{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,7]],"date-time":"2026-11-07T10:30:54Z","timestamp":1794047454466,"version":"4.8.0"},"reference-count":23,"publisher":"Ferrata Storti Foundation (Haematologica)","issue":"6","license":[{"start":{"date-parts":[[2023,11,23]],"date-time":"2023-11-23T00:00:00Z","timestamp":1700697600000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["haematol"],"abstract":"<jats:p>Multiple myeloma (MM) is associated with a wide variety of recurrent genomic alterations. The most common translocation in MM is t(11;14). In this retrospective, single-center, non-interventional study, patients\u2019 bone marrow samples were examined at diagnosis and at relapse(s) following treatment with anti-myeloma regimens to determine whether t(11;14) status was stable over time. This stability cohort consisted of 272 patients, of whom 118 were t(11;14)-positive at diagnosis and 154 were negative. All patients in the stability cohort retained the same t(11;14) status at relapse that they had at diagnosis of MM. Sixteen patients who had t(11;14)-positive MM at diagnosis had multiple longitudinal assessments by fluorescence in situ hybridization (FISH) at relapse events and remained t(11;14)-positive across all timepoints. Patients who had t(11;14)-positive disease at diagnosis of monoclonal gammopathy of unknown significance or smoldering MM also retained t(11;14) positivity through MM diagnosis and relapse. The t(11;14) fusion patterns also remained constant for 90% of patients. For detection of t(11;14), results from FISH and next-generation sequencing (NGS) were compared to determine the rate of concordance between these two methods. This concordance cohort contained 130 patients, of whom 66 had t(11;14)-positive disease and 64 were t(11;14)-negative. In this sample set, the concordance between FISH- and NGS-based detection of t(11;14) was 100%. These results strongly suggest that the t(11;14) rearrangement remains stable during the full disease course in patients with MM and can be detected by FISH- and NGS-based methodologies.<\/jats:p>","DOI":"10.3324\/haematol.2023.284072","type":"journal-article","created":{"date-parts":[[2023,11,23]],"date-time":"2023-11-23T02:58:59Z","timestamp":1700708339000},"page":"1874-1881","source":"Crossref","is-referenced-by-count":3,"title":["t(11;14) status is stable between diagnosis and relapse and concordant between detection methodologies based on fluorescence &lt;i&gt;in situ&lt;\/i&gt; hybridization and next-generation sequencing in patients with multiple myeloma"],"prefix":"10.3324","volume":"109","author":[{"given":"Herv\u00e9","family":"Avet-Loiseau","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rapha\u00eble","family":"Thi\u00e9baut-Millot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaotong","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeremy A.","family":"Ross","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carlos","family":"Hader","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1856","published-online":{"date-parts":[[2023,11,23]]},"reference":[{"key":"62173","doi-asserted-by":"crossref","unstructured":"Elbezanti WO, Challagundla KB, Jonnalagadda SC, Budak-Alpdogan T, Pandey MK. Past, present, and a glance into the future of multiple myeloma treatment. Pharmaceuticals (Basel). 2023; 16(3):415.","DOI":"10.3390\/ph16030415"},{"key":"62174","doi-asserted-by":"crossref","unstructured":"Cardona-Benavides IJ, de Ram\u00f3n C, Guti\u00e9rrez NC. Genetic abnormalities in multiple myeloma: prognostic and therapeutic implications. Cells. 2021; 10(2):336.","DOI":"10.3390\/cells10020336"},{"key":"62175","doi-asserted-by":"crossref","unstructured":"Chng WJ, Glebov O, Bergsagel PL, Kuehl WM. Genetic events in the pathogenesis of multiple myeloma. Best Pract Res Clin Haematol. 2007; 20(4):571-596.","DOI":"10.1016\/j.beha.2007.08.004"},{"key":"62176","doi-asserted-by":"crossref","unstructured":"Walker BA, Wardell CP, Johnson DC. Characterization of IGH locus breakpoints in multiple myeloma indicates a subset of translocations appear to occur in pregerminal center B cells. Blood. 2013; 121(17):3413-3419.","DOI":"10.1182\/blood-2012-12-471888"},{"key":"62177","doi-asserted-by":"crossref","unstructured":"Avet-Loiseau H, Attal M, Moreau P. Genetic abnormalities and survival in multiple myeloma: the experience of the Intergroupe Francophone du My\u00e9lome. Blood. 2007; 109(8):3489-3495.","DOI":"10.1182\/blood-2006-08-040410"},{"key":"62178","doi-asserted-by":"crossref","unstructured":"Fonseca R, Blood EA, Oken MM. Myeloma and the t(11;14) (q13;q32); evidence for a biologically defined unique subset of patients. Blood. 2002; 99(10):3735-3741.","DOI":"10.1182\/blood.V99.10.3735"},{"key":"62179","doi-asserted-by":"crossref","unstructured":"Bal S, Kumar SK, Fonseca R. Multiple myeloma with t(11;14): unique biology and evolving landscape. Am J Cancer Res. 2022; 12(7):2950-2965.","DOI":"10.3390\/cancers14122965"},{"key":"62180","doi-asserted-by":"crossref","unstructured":"Punnoose EA, Leverson JD, Peale F. Expression profile of BCL-2, BCL-XL, and MCL-1 predicts pharmacological response to the BCL-2 selective antagonist venetoclax in multiple myeloma models. Mol Cancer Ther. 2016; 15(5):1132-1144.","DOI":"10.1158\/1535-7163.MCT-15-0730"},{"key":"62181","doi-asserted-by":"crossref","unstructured":"Moreau P, Chanan-Khan A, Roberts AW. Promising efficacy and acceptable safety of venetoclax plus bortezomib and dexamethasone in relapsed\/refractory MM. Blood. 2017; 130(22):2392-2400.","DOI":"10.1182\/blood-2017-06-788323"},{"key":"62182","doi-asserted-by":"crossref","unstructured":"Hebraud B, Caillot D, Corre J. Lost and gain of t(4;14) and t(11;14) in multiple myeloma patients between relapse and diagnosis: an illustration of clonal dynamic during disease course. an IFM study. Blood. 2012; 120(21):196.","DOI":"10.1182\/blood.V120.21.196.196"},{"key":"62183","doi-asserted-by":"crossref","unstructured":"Merz M, Jauch A, Hielscher T. Longitudinal fluorescence in situ hybridization reveals cytogenetic evolution in myeloma relapsing after autologous transplantation. Haematologica. 2017; 102(8):1432-1438.","DOI":"10.3324\/haematol.2017.168005"},{"key":"62184","doi-asserted-by":"crossref","unstructured":"Bolli N, Avet-Loiseau H, Wedge DC. Heterogeneity of genomic evolution and mutational profiles in multiple myeloma. Nat Commun. 2014; 5:2997.","DOI":"10.1038\/ncomms3997"},{"key":"62185","doi-asserted-by":"crossref","unstructured":"Lu G, Muddasani R, Orlowski RZ. Plasma cell enrichment enhances detection of high-risk cytogenomic abnormalities by fluorescence in situ hybridization and improves risk stratification of patients with plasma cell neoplasms. Arch Pathol Lab Med. 2013; 137(5):625-631.","DOI":"10.5858\/arpa.2012-0209-OA"},{"key":"62186","doi-asserted-by":"crossref","unstructured":"Ha J, Cho H, Lee TG. Cytogenetic testing by fluorescence in situ hybridization is improved by plasma cell sorting in multiple myeloma. Sci Rep. 2022; 12(1):8287.","DOI":"10.1038\/s41598-022-11676-w"},{"key":"62187","doi-asserted-by":"crossref","unstructured":"Kumar S, Kaufman JL, Gasparetto C. Efficacy of venetoclax as targeted therapy for relapsed\/refractory t(11;14) multiple myeloma. Blood. 2017; 130(22):2401-2409.","DOI":"10.1182\/blood-2017-06-788786"},{"key":"62188","doi-asserted-by":"crossref","unstructured":"Kumar SK, Harrison SJ, Cavo M. Venetoclax or placebo in combination with bortezomib and dexamethasone in patients with relapsed or refractory multiple myeloma (BELLINI): a randomised, double-blind, multicentre, phase 3 trial. Lancet Oncol. 2020; 21(12):1630-1642.","DOI":"10.1016\/S1470-2045(20)30525-8"},{"key":"62189","unstructured":"A study of venetoclax and dexamethasone compared with pomalidomide and dexamethasone in participants with relapsed or refractory multiple myeloma. 2023."},{"key":"62190","doi-asserted-by":"crossref","unstructured":"Frankel D, Nanni I, Ouafik L. Comparison between immunocytochemistry, FISH and NGS for ALK and ROS1 rearrangement detection in cytological samples. Int J Mol Sci. 2022; 23(18):10556.","DOI":"10.3390\/ijms231810556"},{"key":"62191","doi-asserted-by":"crossref","unstructured":"Bolli N, Li Y, Sathiaseelan V. A DNA target-enrichment approach to detect mutations, copy number changes and immunoglobulin translocations in multiple myeloma. Blood Cancer J. 2016; 6(9):e467.","DOI":"10.1038\/bcj.2016.72"},{"key":"62192","doi-asserted-by":"crossref","unstructured":"Tschautscher MA, Jevremovic D, Buadi FK. Utility of repeating bone marrow biopsy for confirmation of complete response in multiple myeloma. Blood Cancer J. 2020; 10(10):95.","DOI":"10.1038\/s41408-020-00363-6"},{"key":"62193","doi-asserted-by":"crossref","unstructured":"Yellapantula V, Hultcrantz M, Rustad EH. Comprehensive detection of recurring genomic abnormalities: a targeted sequencing approach for multiple myeloma. Blood Cancer J. 2019; 9(12):101.","DOI":"10.1038\/s41408-019-0264-y"},{"key":"62194","doi-asserted-by":"crossref","unstructured":"Boyle EM, Ashby C, Tytarenko RG. BRAF and DIS3 mutations associate with adverse outcome in a long-term follow-up of patients with multiple myeloma. Clin Cancer Res. 2020; 26(10):2422-2432.","DOI":"10.1158\/1078-0432.CCR-19-1507"},{"key":"62195","doi-asserted-by":"crossref","unstructured":"Mohamed SF, Khan M, Quesada A. Disease characteristics of multiple myeloma involving BRAF mutations. Blood. 2021; 138(Suppl 1):4755.","DOI":"10.1182\/blood-2021-147400"}],"container-title":["Haematologica"],"original-title":[],"link":[{"URL":"https:\/\/haematologica.org\/article\/download\/haematol.2023.284072\/76296","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/haematologica.org\/article\/download\/haematol.2023.284072\/77067","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/haematologica.org\/article\/download\/11354\/76296","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,11,7]],"date-time":"2026-11-07T10:05:16Z","timestamp":1794045916000},"score":1,"resource":{"primary":{"URL":"https:\/\/haematologica.org\/article\/view\/haematol.2023.284072"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,11,23]]},"references-count":23,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2024,6,1]]}},"URL":"https:\/\/doi.org\/10.3324\/haematol.2023.284072","relation":{},"ISSN":["1592-8721","0390-6078"],"issn-type":[{"value":"1592-8721","type":"electronic"},{"value":"0390-6078","type":"print"}],"subject":[],"published":{"date-parts":[[2023,11,23]]}}}